Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages
Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close.
ZyCoV-D is the world's first approved DNA vaccine, and the first Covid-19 vaccine in India to be approved for use in adolescents 12 years and above
Zydus Cadila's Covid vaccine ZyCoV-D will be given
IT company AGC Networks on Monday said its board has approved the appointment of Essar Group's Anshuman Ruia as executive director of the company
Both drugs, Mifegest Cytolog are used for medical termination of pregnancy
Shares of Cadila Healthcare Ltd jumped 7.9% on Monday after India last week approved the drugmaker's Covid-19 vaccine for emergency use in adults and children aged 12 years and above
In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector
Cadila Healthcare on Thursday said its wholly-owned subsidiary Zydus Animal Health and Investment has completed sale of its animal healthcare established markets
Cadila Healthcare's stock has taken base near Rs 600 levels on two occasions recently, forming a good support zone
Viona Pharmaceuticals Inc is recalling over 21,000 bottles of metformin hydrochloride extended-release tablets manufactured by Ahemdabad-based Cadila Healthcare
Cadila Healthcare and Bayer (South East Asia) have decided to extend the operations of their joint venture by three years with effect from June
Company says product helps treating mild coronavirus patients and reduces hospitalisation.
We are sure that ZAHL will continue to grow and strengthen its position, said Pankaj Patel
The deal is to sell one of Cadila's two businesses on a slump sale basis as a going concern, for a lump sum of Rs 2,921 cr on cash-free and debt-free basis
Approval from the drug regulator follows late-stage study of the medicine
The company is conducting phase 3 efficacy trials on a three-dose regimen of its DNA plasmid technology-based Covid-19 vaccine, which is in its last leg
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
Price-wise, BPCL's stock seems to have a sturdy structure on the weekly time frame and, looking at the lower degree chart, the recent price correction appears to have completed
The stock price of Cadila Healthcare has broken out from the consolidation which held for last three weeks